Deutsche Bank upgraded AstraZeneca's stock rating from Sell to Hold following mixed results from its drug trials. The lung disease drug tozorakimab showed strong Phase III results and received FDA priority review, signaling potential future growth. However, AstraZeneca's breast cancer drug Etcamah failed to meet its primary endpoint in a late-stage study, posing a setback. The upgrade reflects cautious optimism amid these contrasting outcomes, with an FDA decision on tozorakimab expected in early 2027.
Following Deutsche Bank's upgrade of AstraZeneca from Sell to Hold, the stock is currently trading at USD 161.62 on Pluang as of Sep 15, 2026 20:58 WIB, down 1.32% for the day. Despite the cautious optimism from the upgrade, AstraZeneca remains well below its 52-week high of USD 209.48, with a market cap of $254.94 billion and a dividend yield of 1.96%.
